



Alameda Alliance for Health

FORMULARY UPDATE

**Effective 05/06/2024, unless indicated
below under Committee Actions.**

Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions

The P&T Committee reviewed the efficacy, safety, cost, and utilization profiles of the following therapeutic categories and drug monographs at the March 19, 2024 meeting:

Therapeutic/Monograph Class Reviews	
<ul style="list-style-type: none">• Inhaled Corticosteroids/Long-Acting Beta-Agonists (ICS/LABA) class review• First generation antihistamines class review• Opioid containing antitussives class review• Zepbound monograph	<ul style="list-style-type: none">• Methergine monograph• Casgevy monograph• Lyfgenia monograph• Direct oral anticoagulants class review• SGLT2s class review

The P&T Committee approved the following modifications to the formulary for the Alliance's Group Care programs.

Generic//Biosimilar Name & Strength/Dosage Form	Brand Name	Committee Actions
dabigatran 75 mg Capsule	Pradaxa Oral Capsule 75 MG	Update to Non-Formulary (NF)
dabigatran 150 mg Capsule	Pradaxa Oral Capsule 150 MG	Update to NF
dapagliflozin 5 mg tablet	Farxiga 5 MG tablet	Update to formulary with Step Therapy (ST) (trial and failure of one of the following: metformin, branded/generic drugs containing metformin, branded ARNi, generic ACEi, generic ARB, generic mineralocorticoid receptor antagonists (MRAs) or generic beta blockers)
dapagliflozin 10 mg tablet	Farxiga 10 MG Tablet	Update to formulary with ST (trial and failure of one of the following: metformin, branded/generic drugs containing metformin, branded ARNi, generic ACEi, generic ARB, generic mineralocorticoid receptor antagonists (MRAs) or generic beta blockers)
ertugliflozin 5 mg tablet	Steglatro 5 MG Tablet	Update to formulary with ST (trial and failure of one of the following: metformin, branded/generic drugs containing metformin, branded ARNi, generic ACEi, generic ARB, generic mineralocorticoid receptor antagonists (MRAs) or generic beta blockers)
ertugliflozin 15 mg tablet	Steglatro 15 MG Tablet	Update to formulary with ST (trial and failure of one of the following: metformin, branded/generic drugs containing metformin, branded ARNi, generic ACEi, generic ARB, generic mineralocorticoid receptor antagonists (MRAs) or generic beta blockers)
dapagliflozin; metformin hydrochloride 2.5 mg-1,000 mg tablet, extended release	Xigduo XR 2.5 mg-1,000 mg Tablet, Extended Release	Update to formulary with ST (trial and failure of one of the following: metformin, branded/generic drugs containing metformin, branded ARNi, generic ACEi, generic ARB, generic mineralocorticoid receptor antagonists (MRAs) or generic beta blockers)
dapagliflozin; metformin hydrochloride 5 mg-500 mg tablet, extended release	Xigduo XR 5 mg-500 mg tablet, Extended release	Update to formulary with ST (trial and failure of one of the following: metformin, branded/generic drugs containing metformin, branded ARNi, generic ACEi, generic ARB, generic mineralocorticoid receptor antagonists (MRAs) or generic beta blockers)

dapagliflozin; metformin hydrochloride 5 mg-1,000 mg tablet, extended release	Xigduo XR 5 mg-1,000 mg Tablet, Extended release	Update to formulary with ST (trial and failure of one of the following: metformin, branded/generic drugs containing metformin, branded ARNi, generic ACEi, generic ARB, generic mineralocorticoid receptor antagonists (MRAs) or generic beta blockers)
dapagliflozin; metformin hydrochloride 10 mg-500 mg tablet, extended release	Xigduo XR 10 MG - 500 MG Tablet, Extended Release	Update to formulary with ST (trial and failure of one of the following: metformin, branded/generic drugs containing metformin, branded ARNi, generic ACEi, generic ARB, generic mineralocorticoid receptor antagonists (MRAs) or generic beta blockers)
dapagliflozin; metformin hydrochloride 10 mg-1,000 mg tablet, extended Release	Xigduo XR 10 MG - 1,000 MG Tablet, Extended Release	Update to formulary with ST (trial and failure of one of the following: metformin, branded/generic drugs containing metformin, branded ARNi, generic ACEi, generic ARB, generic mineralocorticoid receptor antagonists (MRAs) or generic beta blockers)
ertugliflozin/metformin 2.5 mg-500 mg tablet	Segluromet 2.5 MG - 500 MG Tablet	Update to formulary with ST (trial and failure of one of the following: metformin, branded/generic drugs containing metformin, branded ARNi, generic ACEi, generic ARB, generic mineralocorticoid receptor antagonists (MRAs) or generic beta blockers)
ertugliflozin/metformin 2.5 mg-1,000 mg tablet	Segluromet 2.5 MG - 1,000 MG Tablet	Update to formulary with ST (trial and failure of one of the following: metformin, branded/generic drugs containing metformin, branded ARNi, generic ACEi, generic ARB, generic mineralocorticoid receptor antagonists (MRAs) or generic beta blockers)
ertugliflozin/metformin 7.5 mg-500 mg tablet	Segluromet 7.5 MG - 500 MG Tablet	Update to formulary with ST (trial and failure of one of the following: metformin, branded/generic drugs containing metformin, branded ARNi, generic ACEi, generic ARB, generic mineralocorticoid receptor antagonists (MRAs) or generic beta blockers)
ertugliflozin/metformin 7.5 mg-1,000 mg tablet	Segluromet 7.5 MG - 1,000 MG Tablet	Update to formulary with ST (trial and failure of one of the following: metformin, branded/generic drugs containing metformin, branded ARNi, generic ACEi, generic ARB, generic mineralocorticoid receptor antagonists (MRAs) or generic beta blockers)
ertugliflozin, sitagliptin 5 mg-100 mg tablet	Steglujan 5 mg-100 MG Tablet	Update to Formulary with Prior Authorization (PA)
ertugliflozin, sitagliptin 15 mg-100 mg tablet	Steglujan 15 MG -100 MG Tablet	Update to Formulary with PA

PRIOR AUTHORIZATION GUIDELINE UPDATES

Inhaled Corticosteroids/Long-Acting Beta-Agonists (ICS/LABA)	Combinations MRG (part of ICS/LABA class review)
Oxbryta (voxelotor)	Angiotensin II Receptor Blockers and Renin Inhibitors
Histamine H2 Receptor Antagonists	Presbyopia Agents
Zurzuvae	Dificid
Fabhalta	SGLT2s class review
Corlanor (ivabradine)	Ezetimibe (Zetia)
Pulmonary Arterial Hypertension (PAH) Criteria	Brilinta (ticagrelor) tablet
GLP-1 Agonists, SGLT2 inhibitors, DPP-4 Inhibitors and Combinations	Parkinson's Disease Agents
PCSK-9 Monoclonal Antibodies (mAbs)	Xolair (omalizumab) for Asthma and Urticaria
Agents for Atopic Dermatitis	Pulmonary Biologics for Asthma and Eosinophilic Conditions
Biologic Agents for Nasal Polyposis	Estrogen Patches and Injectables - RETIRE
Emflaza	

PRIOR AUTHORIZATION GUIDELINES REVIEWED (NO UPDATES)

Ophthalmic Antihistamines	Verquvo
Siklos (hydroxyurea)	Tadalafil (Cialis) for BPH
Altoprev (lovastatin ER) and Fluvastatin, Fluvastatin ER	Arikayce (amikacin)
Long-Acting Muscarinic /Long-Acting Beta Agonist/ Corticosteroid inhaled Triple Combination Products	Savella (milnacipran) tablet
Fexofenadine-pseudoephedrine	Injectable Anticoagulants
Atovaquone (Mepron)	Thrombocytopenia Agents
Travoprost (Travatan Z) ophthalmic drops	Pyridostigmine (Mestinon)
Antifibrotic Respiratory Tract Agents	Cystic Fibrosis Agents
Elmiron (pentosane polysulfate)	Linezolid
Symlin (pramlintide)	Corticosteroid Preparations to Treat Hemorrhoids

**For questions, please contact the Alliance's Pharmacy Services department at:
(510) 747-4541.**